- Home
- AZZ vs AKRO Comparison
AZZ vs AKRO Comparison
Compare AZZ & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZZ
- AKRO
- Stock Information
- Founded
- AZZ 1956
- AKRO 2017
- Country
- AZZ United States
- AKRO United States
- Employees
- AZZ N/A
- AKRO N/A
- Industry
- AZZ Industrial Specialties
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- AZZ Industrials
- AKRO Health Care
- Exchange
- AZZ Nasdaq
- AKRO Nasdaq
- Market Cap
- AZZ 2.7B
- AKRO 2.8B
- IPO Year
- AZZ N/A
- AKRO 2019
- Fundamental
- Price
- AZZ $81.00
- AKRO $37.63
- Analyst Decision
- AZZ Strong Buy
- AKRO Strong Buy
- Analyst Count
- AZZ 8
- AKRO 9
- Target Price
- AZZ $100.71
- AKRO $76.29
- AVG Volume (30 Days)
- AZZ 251.7K
- AKRO 1.3M
- Earning Date
- AZZ 04-21-2025
- AKRO 05-09-2025
- Dividend Yield
- AZZ 0.83%
- AKRO N/A
- EPS Growth
- AZZ N/A
- AKRO N/A
- EPS
- AZZ 1.28
- AKRO N/A
- Revenue
- AZZ $1,592,438,000.00
- AKRO N/A
- Revenue This Year
- AZZ $4.84
- AKRO N/A
- Revenue Next Year
- AZZ $5.21
- AKRO N/A
- P/E Ratio
- AZZ $63.26
- AKRO N/A
- Revenue Growth
- AZZ 5.63
- AKRO N/A
- 52 Week Low
- AZZ $69.59
- AKRO $17.86
- 52 Week High
- AZZ $99.49
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- AZZ 44.22
- AKRO 43.61
- Support Level
- AZZ $80.24
- AKRO $36.46
- Resistance Level
- AZZ $84.38
- AKRO $39.13
- Average True Range (ATR)
- AZZ 4.52
- AKRO 3.04
- MACD
- AZZ 0.32
- AKRO 0.06
- Stochastic Oscillator
- AZZ 59.80
- AKRO 57.38
About AZZ AZZ Inc.
AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. In its Metal Coatings segment, the company offers metal finishing services to protect against corrosion, such as hot dip galvanizing, spin galvanizing, powder coating, anodizing, and plating. The Precoat Metals Segment offers aesthetic and corrosion-resistant coatings for steel and aluminum coils.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.